DC
MGX icon

Diametric Capital’s Metagenomi Therapeutics MGX Stock Holding History

Diametric Capital’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-49,285
Closed -$67K – 405
2025
Q1 		$67K Buy
49,285
+7,670
+18% +$18.3K 0.08% 184
2024
Q4 		$150K Buy
+41,615
New +$100K 0.1% 255

Other funds holding MGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVGI
Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Diametric Capital's MGX Position: Q2 2025 in Review

Diametric Capital sold out of Metagenomi Therapeutics (MGX) in Q2 2025, closing a stake of 49,285 shares — an estimated $67K sold.

Diametric Capital first reported a position in MGX in Q4 2024 and held it in 2 quarters. The position peaked at $150K in Q4 2024. 69 funds tracked by Wall St. Rank hold MGX as of Q2 2025.

  • Diametric Capital reported no remaining Metagenomi Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Diametric Capital sold 49,285 Metagenomi Therapeutics shares in Q2 2025, an estimated $67K.
  • Diametric Capital first reported a position in Metagenomi Therapeutics in Q4 2024 and held it in 2 quarters.
  • Diametric Capital's Metagenomi Therapeutics position peaked at $150K in Q4 2024.
  • 69 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2025.

Based on Diametric Capital's 13F filing for Q2 2025, filed 13 Aug 2025.